[ad_1]
November 21, 2025
5 min watch
Key takeaways:
- New evidence presented at ASN Kidney Week explored the pathogenesis of IgA nephropathy (IgAN).
- Newly published clinical trials focus on the efficacy of new drugs for treatment of IgAN.
HOUSTON — In this video, Ali G. Gharavi, MD, discusses a “change in the treatment paradigm” for IgA nephropathy based new pathogenesis evidence and published clinical trials presented at ASN Kidney Week.
“I think this is a really exciting time because now we are going to be able to finally use and have a lot of clinical trials with a lot of different options to help our patients and prevent kidney failure,” Gharavi, Harold Ames Hatch Professor of Medicine and chair of the department of medicine at Columbia University, told Healio.
Sources/Disclosures
Source:
Gharavi AG. Emerging insights in the diagnosis and care of patients with IgAN. Presented at: ASN Kidney Week; Nov. 5-9, 2025; Houston.
Disclosures:
Gharavi reports consulting for Natera, Novartis and Vera Therapeutics.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
[ad_2]
Source link
